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ABSTRACT 
Dendrimers are novel three dimensional, hyperbranched globular nano polymeric architectures. Attractive features like nanoscopic size, 
narrow polydispersity index and excellent control over molecular structure afford dendrimers with ideal drug delivery ability through 
encapsulating drugs in their interior or covalently conjugating drugs on their surfaces. The adaptable surface functionalization ability 
enables covalent conjugation of various targeting molecules onto the surface of dendrimers, thereby allowing for generation of various 
multifunctional nanodevices for targeted drug delivery applications. Drug delivery researchers are especially enthusiastic about possible 
utility of dendrimers as drug delivery tool. However, to get the maximum benefits of these novel class macromolecules, a research by 
collaboration is very much essential. Finally,  it is one of the youngest and exciting fields of polymer researches where all branches of science 
can take part and hence, deserves more intensive attention.  
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1. INTRODUCTION  
The esthetically appealing structures of dendrimers have a 
stimulating and growing interest in different disciplines of 
science. These synthetic macromolecules consist of 
relatively short chains with specific functional groups at 
the ends. Their structure, which is obtained by means of 
suitable iterative stepwise reactions sequences, is 
developed through successive generations and gives rise to 
monodisperse, highly branched tree-like “dendritic” 
morphology. Dendrimers are therefore branched, synthetic 
polymers with layered architectures that show promise in 
several applications. Up to now, dendrimers have been 
widely applied in many fields, such as supramolecular 
chemistry or host–guest chemistry, electrochemistry, 
photochemistry, nanoparticle synthesis, pollution 
management, dye decolorization, preparation of 
monomolecular membranes, curing of epoxy resins, 
catalysis, drug delivery, and gene transfection 1. Among 
them, the use of dendrimers in delivery systems has 
deserved more attentions in recent years 2. By regulating 
dendrimer synthesis, it is possible to precisely manipulate 
both their molecular weight and chemical composition, 
thereby allowing predictable tuning of their 
biocompatibility and pharmacokinetics. Dendrimers offer a 
unique platform for exploring chemical diversity on the 
nanoscale. This unique combination of properties makes 
them ideal candidates for nanotechnology applications in 
both biological and materials sciences such as use of 
dendrimers as drugs in their own, dendrimers as drug 
delivery vehicles or diagnostics 3. 
The potential of dendrimers in treatment of lifestyle and 
civilization diseases such as cancer 4, diabetes, viral and 
microbial infections, Alzheimer etc. has also been 
recognized 5. Mc Carthy et al. 6 conducted  phase 1 human 
clinical trial of dendrimer-enhanced docetaxel 
chemotherapeutic product, referred to as DEP™-Docetaxel 
The primary objective of the study was to establish the 
maximum tolerated dose (MTD) and dose limiting 
toxicities (DLT) of DEP™-Docetaxel, a new formulation of 
the major chemotherapeutic agent, docetaxel, which is 
marketed worldwide under the tradename, Taxotere®.  
The preclinical studies of DEP™-Docetaxel demonstrated 
the significantly superior anti-cancer effectiveness of the 
product compared to Taxotere® across a range of 
important cancer types including breast, prostate, lung and 
ovarian cancer.  In addition, DEP™-Docetaxel exhibited a 
lack of the severe toxicity, neutropenia, which is the most 
important dose-limiting side effect of Taxotere®. Use of 
DEP™ technology also improved the water solubility and 
tissue targeting of docetaxel. 
Bioactivity of the designed dendrimers suggests them as 
promising therapeutic agents in contemporary 
regenerative medicine, involved in wound healing, tissue 
and cartilage reconstruction as well as bone mineralization. 
The potential applications of de novo – designed 
dendrimers in areas such as boron neutron capture 
therapy, as MRI contrast reagents, and materials for 
enhanced transfection cannot be overlooked. Before such 
products can reach the market, however, the field must not 
only address the cost of manufacture and quality control of 
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pharmaceutical-grade materials, but also assess the long-
term human and environmental health consequences of 
dendrimer exposure in vivo. This review will highlight the 
structures, synthesis, properties of dendrimers as well as 
recent studies on the applications of dendrimers. 
2. SYNTHESIS OF DENDRIMERS  
Dendrimers are generally prepared using either divergent 
method or convergent method. There is a fundamental 
difference between these two construction concepts. In the 
divergent methods, dendrimer grows outwards from a 
multifunctional core molecule. The core molecule reacts 
with monomer molecules containing one reactive and two 
dormant groups giving the first generation dendrimer. 
Then the new periphery of the molecule is activated for 
reactions with more monomers. The process is repeated 
for several generations and a dendrimer is built layer after 
layer (Fig. 1). 
  
 
Figure 1: Two different strategies of dendrimer synthesis. Top: divergent strategy, bottom: convergent strategy. 
 
The divergent approach is successful for the production of 
large quantities of dendrimers. Problems occur from side 
reactions and incomplete reactions of the end groups that 
lead to structure defects. To prevent side reactions and to 
force reactions to completion large excess of reagents is 
required. It causes some difficulties in the purification of 
the final product. 
The convergent methods were developed as a response 
to the weaknesses of the divergent synthesis. In the 
convergent approach, the dendrimer is constructed 
stepwise, starting from the end groups and progressing 
inwards. When the growing branched polymeric arms, 
called dendrons, are large enough, they are attached to a 
multifunctional core molecule (Fig. 1). The convergent 
growth method has several advantages. It is relatively easy 
to purify the desired product and the occurrence of defects 
in the final structure is minimised. It becomes possible to 
introduce subtle engineering into the dendritic structure 
by precise placement of functional groups at the periphery 
of the macromolecule. The convergent approach does not 
allow the formation of high generations because steric 
problems occur in the reactions of the dendrons and the 
core molecule 7. 
The first synthesised dendrimers were polyamidoamines 
(PAMAMs). They are also known as “starburst” dendrimers 
(trademark of the Dow Chemicals Company). Ammonia is 
used as the core molecule which reacts with methyl 
acrylate in the presence of methanol and then 
ethylenediamine is added: 
NH3 + 3CH2CHCOOCH3 →N-(CH2CH2COOCH3)3................................(1) 
N-(CH2CH2COOCH3)3+3NH2CH2CH2NH2→N-
(CH2CH2CONHCH2CH2NH2)3+3CH3OH...........(2)     
                                                                                                
The free amino group present at the end react with two 
methyl acrylate monomers and two ethylenediamine 
molecules producing new dendrimer generation. The half-
generation PAMAM dendrimers (e.g., 0.5, 1.5, and 2.5) 
possess anionic surfaces of carboxylate groups. The 
number of reactive surface sites is doubled with every 
generation and the mass increases more than twice. 
Dendritech TM (U.S.A.) manufactures PAMAM dendrimers. 
These are based on either an ethylenediamine (EDA) core 
or ammonia core and possess amino groups on the surface. 
They are usually sold as a solution in either methanol or 
water. DSM (Netherlands) has developed production of 
poly (propylene imine) dendrimers. They are currently 
available under the name Astramol TM. Butylenediamine 
(BDA) is used as the core molecule. The repetitive reaction 
sequence involves Michael addition of acrylonitrile to a 
primary amino group followed by hydrogenation of nitrile 
groups to primary amino groups 8. 
3. MOLECULAR STRUCTURE OF DENDRIMER  
Dendrimers have a globular configuration with monomer 
units branching out from a centre core. The structure is 
highly defined and organized. The number of branches 
increases exponentially extending from core to the 
periphery. The branching would come to a stop when the 
steric hindrance would come to a stop any further growth. 
In general, dendrimers consists of three major regions – 
(a) an initiator core, (b) a shell with extending arms or 
branches made of building blocks and (c) the exterior or 
outer-most surface groups on the termini of the branches 9. 
The monomers that attach to the core form the first 
branches (also called First Generation). The three parts of 
the dendrimer can be specifically tailored towards a 
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desired molecular property or function of the dendrimer 
such as drug delivery, molecular sensors, enzyme mimics, 
etc.  
Dendrimers of lower generations (0, 1, and 2) have highly 
asymmetric shape and possess more open structures as 
compared to higher generation dendrimers. As the chains 
growing from the core molecule become longer and more 
branched (in 4 and higher generations) dendrimers adopt 
a globular structure as represented in Figure 2. 
Dendrimers become densely packed as they extend out to 
the periphery, which forms a closed membrane-like 
structure. When a critical branched state is reached 
dendrimers cannot grow because of a lack of space. This is 
called the ‘starburst effect’. For PAMAM dendrimer 
synthesis it is observed after tenth generation. The rate of 
reaction drops suddenly and further reactions of the end 
groups cannot occur. The tenth generation PAMAM 
contains 6141 monomer units and has a diameter of about 
124 Å. The increasing branch density with generation is 
also believed to have striking effects on the structure of 
dendrimers. They are characterised by the presence of 
internal cavities and by a large number of reactive end 
groups. 
 
Figure 2: Representation of a Fourth Generation 
Dendrimer. 
4. PHYSICOCHEMICAL PROPERTIES OF 
DENDRIMERS 
 Monodispersity and Rheological Properties  
Dendrimers are monodisperse macromolecules, unlike 
linear polymers synthesized step-by-step, have well-
organized structures with a very low polydispersity index 
(Mw/Mn<1.01–1.05). The classical polymerization process 
which results in linear polymers is usually random in 
nature and produces molecules of different sizes, whereas 
size and molecular mass of dendrimers can be specifically 
controlled during synthesis 10. Because of their molecular 
architecture, dendrimers show some significantly 
improved physical and chemical properties when 
compared to traditional linear polymers 11. In solution, 
linear chains exist as flexible coils; in contrast, dendrimers 
form a tightly packed ball. This has a great impact on their 
rheological properties. Dendrimer solutions have 
significantly lower viscosity than linear polymers. When 
the molecular mass of dendrimers increases, their intrinsic 
viscosity goes through a maximum at the fourth generation 
and then begins to decline. Such behaviour is unlike that of 
linear polymers. 
 Solubility and Reactivity 
The solubility of dendrimers is determined by the surface 
functional groups, dendrimer generation, repeated units, 
and even the core. Dendrimers were reported to possess 
perfect solubility in a large number of solvents. Their high 
solubility in organic solvents leads to rapid dissolution and 
provides various approaches to characterize their 
structures. Also, high water-solubility ensures their 
applications as solubility enhancers for hydrophobic guest 
molecules 12. On the other hand, high density of surface 
functional groups (–NH2, –COOH, –OH) in PAMAM 
dendrimers may be expected to conjugate with a series of 
bioactive molecules. These surface-modified dendrimers 
with different functions provide us with new nanodevice 
design strategies. Overall, high solubility and reactivity 
make dendrimers suitable as a platform in biomedical 
fields 13.  
5. EFFECT OF VARIOUS FACTORS ON 
PROPERTIES OF DENDRIMERS 
 Effect of pH: Amino-terminated PPI and PAMAM 
dendrimers have basic surface groups as well as a basic 
interior. For these types of dendrimers with interiors 
containing tertiary amines, the low pH region generally 
leads to extended conformations due to electrostatic 
repulsion between the positively charged ammonium 
groups. Applying molecular dynamics to predict the 
structural behaviour of PAMAM dendrimers as a function 
of pH show that the dendrimer has an extended 
conformation, based on a highly ordered structure at low 
pH (pH ≤4). At this pH, the interior is getting increasingly 
“hollow” as the generation number increases as a result of 
repulsion between the positively charged amines both at 
the dendrimer surface and the tertiary amines in the 
interior. At neutral pH, back-folding occurs which may be a 
consequence of hydrogen bonding between the uncharged 
tertiary amines in the interior and the positively charged 
surface amines. At higher pH (pH ≥ 10) the dendrimer 
contract as the charge of the molecule becomes neutral, 
acquiring a more spherical (globular) structure based on a 
loose compact network, where the repulsive forces 
between the dendrimer arms and between the surface 
groups reaches a minimum 14. At this pH, the conformation 
has a higher degree of back-folding as a consequence of the 
weak “inter-dendron” repulsive forces (Figure 3). 
Dendrimers (G5–G7) are conformationally more affected 
by change in pH and ionic strength in comparison to higher 
generation dendrimers (e.g. G8). The reason for this may 
be found in the somewhat more restricted motion of the 
outer shell chain segments in the higher generation 
dendrimers, leading to a more globular-shaped molecule 
despite different conditions in the surroundings 15. 
  
Gupta et al                                                                                                         Journal of Drug Delivery & Therapeutics. 2018; 8(6-s):328-339   
ISSN: 2250-1177                                                                                 [331]                                                                                  CODEN (USA): JDDTAO 
 
Figure 3: Three-dimensional structure of a G6-PAMAM dendrimer, under different pH. 
 
 Effect of solvent: The ability of the solvent to solvate 
the dendrimer structure is a very important parameter 
when investigating the conformational state of a 
dendrimer. Molecular dynamics has been applied to study 
the variation of dendrimer conformation as a function of 
dendrimer generation in different solvents. Dendrimers of 
all generations generally all experience a larger extend of 
back-folding with decreasing solvent quality, i.e. decreasing 
solvation. However, being more flexible, the low generation 
dendrimers show the highest tendency towards back-
folding as a result of poor solvation compared to the higher 
generation dendrimers. NMR studies performed on PPI 
dendrimers conclude that an apolar solvent like benzene, 
poorly solvates the dendrons favouring intramolecular 
interactions between the dendrimer segments and back-
folding. However, a weakly acidic solvent like chloroform 
can act as a hydrogen donor for the interior amines in a 
basic dendrimer like PPI, leading to an extended 
conformation of the dendrimer because of extensive 
hydrogen bonding between the solvent and the dendrimer 
amines 16. Both experimental as well as theoretical studies 
on amino-terminated PPI and PAMAM dendrimers (polar 
dendrimers) show the tendency that apolar aprotic 
(“poor”) solvents induce higher molecular densities in the 
core region as a result of back-folding, whereas polar 
(“good”) solvents solvate the dendrimer arms and induce a 
higher molecular density on the dendrimer surface. 
Interestingly, dendrimers having polar surface groups to 
some extent resemble proteins in their conformational 
behaviour when subjecting these structures to more apolar 
conditions, in the sense that back-folding of the polar 
surface groups may expose the more hydrophobic 
dendrimer parts to the surroundings leading to a 
decreased surface polarity of the back-folded dendrimer. A 
similar behaviour has been observed in the adsorption of 
proteins onto hydrophobic surfaces 17, giving a highly 
denaturated (unfolded) state of the protein exposing its 




Figure 4: Proposed scheme for solvation of a dendrimer under different solvent conditions. 
Left: Solvation of a polar dendrimer in a protic solvent (“good”), solvent leading to extended conformation exposing a polar 
surface.  
Right: Polar dendrimer in an apolar aprotic solvent (“poor”), solvent leading to exposure of an apolar surface consisting of 
alkyl chains by back-folding. 
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 Effect of Salt: Molecular simulations generally 
conclude that high ionic strength (high concentration of 
salts) has a strong effect on charged PPI dendrimers and 
favours a contracted conformation of dendrimers, with a 
high degree of back-folding somewhat similar to what is 
observed upon increasing pH or poor salvation 18.  At low 
salt conditions, the repulsive forces between the charged 
dendrimer segments results in an extended conformation 
in order to minimise charge repulsion in the structure 
(Figure 5). 
 
Figure 5: Showing the three-dimensional 
conformational change of a PPI dendrimer upon 
increasing ionic strength 
 Effect of Concentration: In dendrimers with flexible 
structures the conformation is not only affected by small 
molecules like solvents, salts or protons, but may also be 
sensitive to larger objects, such as other dendrimers or 
surfaces which can have a great affect on the molecular 
density and conformation of the dendrimer. Small angle X-
ray scattering (SAXS) experiments performed on PPI 
dendrimers (G4, G5) in a polar solvent like methanol show 
that the molecular conformation of dendrimers upon 
increasing concentration becomes increasingly contracted. 
This molecular contraction may minimise the repulsive 
forces between the dendrimer molecules and increase the 
ability of the dendrimers to exhibit a more tight 
intermolecular packing 19. 
6. CHARACTERIZATION OF DENDRIMERS 
The characterization of dendrimers is rather complex due 
to the size and symmetry of these macromolecules. Various 
NMR techniques (1H, 13C, 15N, 31P), elemental analyses, 
and chromatography techniques (HPLC, SEC) are widely 
used, but these techniques cannot reveal small amounts of 
impurities in, especially, higher generation dendrimers.  
Fortunately, recent progress in ESI (electrospray 
ionization) and MALDI (matrix-assisted laser desorption 
ionization) mass spectrometry allows for an in-depth 
analysis of dendrimers. ESI-MS has been used to identify 
the imperfections in both poly(propylene imine) and 
poly(amidoamine) dendrimers (PAMAM). Both of these 
dendrimer types are made via a divergent synthesis and 
are very suitable for electro spray ionization due to their 
polar and basic nature 20. 
 Spectroscopy Techniques 
Nuclear Magnetic Resonance (NMR): NMR is mainly used 
for analyzing step by step synthesis of dendrimer, to probe 
the size, morphology, dynamics of dendrimers for organic 
dendrimers such as PPI and polyphenylester.  
 UV-Visible Spectroscopy: UV-Visible Spectroscopy can be 
used to monitor the synthesis of dendrimers, The intensity 
of the absorption band is essentially proportional to the 
number of chromophoric units, and can be a test for the 
purity of PPI dendrimers having azobenzene as end 
groups, for phosphorus dendrimers having azobenzenes 
within the branches, or double-layered carbosilane 
dendrimers 21,22. 
Infra-red (IR) and Raman Spectroscopy: Infra-red 
spectroscopy is mainly used for routine analysis of the 
chemical transformations occurring at the surface of 
dendrimers, such as the disappearance of nitrile groups in 
the synthesis of PPI dendrimers , the occurrence of 
hydrogen bonding in PPI glycine functionalized 
dendrimers   or the disappearance of the aldehydes during 
synthesis of PMMH dendrimers. Infra red spectroscopy 
(IR) for routine analysis of the chemical transformations 
occurring at the surface of dendrimers and to characterize 
delocalize π-π stacking interaction between end groups of 
modified PAMAM. Raman spectroscopy gave relevant 
information about the degree of cyclodehydrogenation of 
polyphenylene dendrimers, and the characterization of PPI 
and phosphorus dendrimers. 
Fluorescence: The high sensitivity of fluorescence has 
been used to quantify defects during the synthesis of 
dendrimers, such as unreacted CO2H groups in ARB 
dendrimers, but its main use is to characterize the 
structure of dendrimers having photochemical probes 
covalently linked to one particular section.  
X-ray diffraction: This technique should allow precise 
determination of the chemical composition, size and shape 
of dendrimers. 
Mass spectrometry: Classical Mass Spectrometry 
techniques such as chemical ionization or fast atom 
bombardment (FAB) can be used only for the 
characterization of small dendrimers, whose mass is below 
3000 D.  
 Scattering Techniques 
Small angle X-ray scattering (SAXS) gives information 
about their average radius of gyration (Rg) in solution. The 
intensity of the scattering as a function of angle also 
provides information on the arrangement of polymer 
segments, hence on the segment density distribution 
within the molecule 23. 
Small angle neutron scattering (SANS) gives access to the 
radius of gyration, but may also reveal more accurate 
information than SAXS about the internal structure of the 
entire dendrimer. The location of the end groups has also 
been determined by SANS experiments conducted with 
PAMAM dendrimers and PPI dendrimers having labelled 
(deuterated) or unlabelled end groups. 
Laser light scattering (LLS) to determine the 
hydrodynamic radius of dendrimers, Dynamic LLS is used 
for the detection of aggregates. 
 Microscopy Methods 
Transmission Electron Microscopy and Scanning 
Electron Microscopy are mainly used for the imaging of 
dendrimers. Visualizing single molecules by optical 
microscopy has been successfully carried out for 
dendrimers having a fluorescent core. Confocal microscopy 
allowed one to observe the fluorescence of a third 
generation PBzE dendrimer having a dihydropyrrolo 
pyrroledione as a core and polyphenylene dendrimers 
having peryleneimide as end groups. 
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 Size Exclusion Chromatography 
  Size Exclusion Chromatography (SEC) allows the separation 
of molecules according to size. A detector such as a 
differential refractive index or a LLS detector is connected 
to the SEC apparatus for the determination of the 
polydispersity, which is generally very close to unity. Most 
types of dendrimers are characterized by SEC, even self 
assembled dendrimers 24. 
  Electrical Techniques 
Electron paramagnetic resonance (EPR) is the 
Quantitative determination of substitution efficiency on 
the surface of PAMAM dendrimers 25. 
Electrochemistry gives information about the possibility 
of interaction of electroactive end groups. 
Electrophoresis used for the assessment of puritity and 
homogeneity of several types of water soluble dendrimers. 
Electro Spray Ionisation (ESI) can be used for dendrimers 
able to form stable multicharged species. It has been 
applied to PPI dendrimers and to PAMAM dendrimers up 
to generations. Electrospray ionization can be used for 
dendrimers able to form stable multicharged species 26. 
  Rheology And Physical Properties 
Intrinsic viscosity: Rheology, and particularly dilute 
solution viscometric studies, can be used as analytical 
probe of the morphological structure of dendrimers. 
Differential Scanning Calorimetry (DSC): The DSC 
technique is generally used to detect the glass transition 
temperature (Tg), which depends on the molecular weight, 
entanglement and chain-end composition of polymers. The 
Tg is affected by the end group substitutions, and the 
molecular mass of dendrimers. 
Dielectric Spectroscopy (DS): Dielectric Spectroscopy 
gives information about molecular dynamic processes in 
polymers (a-, h-, g- and y-relaxation) 27. 
 Miscellaneous 
X-ray Photoelectron Spectroscopy (XPS): chemical 
composition of dendrimers such as poly (aryl ether) 
dendrons or PMMH dendrimers has been also obtained 
using XPS, this technique is most generally used for the 
characterization of layers, Sedimentation for lactosylated 
PAMAM dendrimers, measurements of dipole moments for 
PMMH dendrimer. Titrimetry used to determine the 
number of NH2 end groups of PAMAM dendrimers. 
7. APPLICATIONS OF DENDRIMERS 
 Pharmaceutical Application 
Dendrimers in Oral Drug Delivery: Dendrimers may act 
as potential candidates for orally controlled release 
systems by conjugating/encapsulating drug molecules 
to/in them. They allow the maintenance of drug 
concentrations within the therapeutic range at the injured 
regions, and hence can simplify dosing schedules. In 
addition, dendrimers can significantly increase the 
solubility of orally administrated drugs and even the 
stability of drugs in biological environments. These 
macromolecules with bioadhesive properties have strong 
affinity for mucosa and can prolong the residence time of 
the orally administrated drug in contact with the intestinal 
epithelium. Furthermore, dendrimers themselves can 
easily penetrate through intestinal membranes, and thus 
can enhance the oral absorption of low-penetration drugs. 
These properties make dendrimers suitable carriers for 
the development of oral drug delivery systems 28.  It was 
suggested that colloidal drug carriers such as dendrimers 
could be absorbed by way of the Peyer’s patches, which is a 
route to enhance the oral absorption of encapsulated drug 
molecules and to minimize enzymatic degradation in the 
intestine tissue 29. Experimental results showed a 
preferential uptake of dendrimers through the lymphoid 
tissue in the small intestine but not in the large intestine. 
The percentage of the initial dose absorbed through the 
lymphoid tissue was comparatively greater than that 
through the nonlymphoid tissue of the small intestine. 
These results indicated that dendrimers were capable to 
enhance the absorption of low penetration drugs in the 
small intestine tissues. Dendrimer size was a key factor on 
determining overall uptake. Macromolecules with 
diameters up to 3 nm may penetrate through the intestinal 
membranes via either the transcellular or paracellular 
pathway 30. Therefore, G2.5 and G3.5 PAMAM dendrimers 
could transport across the intestine via these ways. On the 
other hand, G4 and higher generation PAMAM dendrimers 
could attach to the invaginating plasma membrane, and 
enter cells by specific or nonspecific adsorptive 
endocytosis. G2.5 and G3.5 PAMAM dendrimers showed 
particularly low tissue uptake ability, while G5.5 PAMAM 
dendrimer displayed a higher tissue accumulation than 
G2.5 and G3.5 dendrimers. Moreover, cationic dendrimers 
showed a different pattern of accumulation from anionic 
dendrimers. The negatively charged cell membrane could 
interact strongly with cationic molecules, and hence led to 
higher tissue association and lower transport rate of these 
dendrimers. These results indicated that dendrimers 
exhibited a size/conformation/charge sensitivity of the 
transport mechanism across the intestine 31. 
5-FU, a well-known anti-cancer drug, has high toxic side 
effects in clinical practice. Several attempts have been done 
to reduce its toxicity by using polymeric carriers. Tripathi 
et al. 32 modified the surface groups of PAMAM dendrimers 
with fatty acid molecules and then coated the obtained 
dendrimer grafts by phospholipids. The dendritic 
structures were then used to encapsulate 5-FU and 
employed as potential oral drug carriers. In vivo 
pharmacokinetic parameters and bioavailability were 
determined from the blood concentration of 5-FU 
performed in albino rats. The dendrimer-drug formulation 
was found to be significantly more effective than free drugs 
after oral administration.  
Dendrimers in Transdermal Drug Delivery: PAMAM 
dendrimers can improve either the water-solubility or 
stability of hydrophobic drugs. These materials with 
hydrophilic outer shells and hydrophobic interiors, which 
accord with structural requirement of polymeric 
transdermal enhancers, are expected to act as effective 
penetration enhancers. Wang et al. 33 reported the 
utilization of polyhydroxyalkanoate (PHA) and G3 PAMAM 
dendrimer as a novel TDDS. PHA used by researchers was 
composed of 3-hydroxyhexanoic acid (8%) and 3-
hydroxyoctanoic acid (92%). Before the in vitro 
permeation experiments was performed on snake skins, 
PHA and the model drug (tamsulosin hydrochloride) were 
mixed together and laid on the transdermal delivery 
patches. In order to determine the effect of the PAMAM 
dendrimer on in vitro penetration efficiency of tamsulosin 
hydrochloride, they pretreated the snake skin with 
PAMAM dendrimer solution for 24 h. However, no 
significant enhancement of permeation amount of the 
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model drug was found. When PAMAM dendrimer was 
coadministrated with the PHA matrix, the penetration 
amount of tamsulosin in the dendrimer-containing PHA 
matrix was 24.0 mg/cm2/day while that in the dendrimer-
lacking PHA matrix was 15.7 mg/cm2/ day (the required 
amount of this drug in clinical trials is 20 mg/cm2/day). 
Thus, the authors concluded that PHA-dendrimer matrix 
reached the clinical aim and could be developed as a useful 
delivery system for clinical TDDS. In a separate 
experiment, the same team reported the mechanism of 
enhancement effect of dendrimer on drug penetration 
through the skin in TDDS 34.  G3 PAMAM dendrimer with 
amino groups and G2.5 PAMAM dendrimer with carboxyl 
groups were used. The results showed that only cationic 
dendrimers could increase the penetration ability of 
tamsulosin hydrochloride through the skin. To clarify the 
mechanism of this enhancement effect by cationic 
dendrimers, the authors accidentally found that tamsulosin 
hydrochloride formed crystal in the cationic 
dendrimer/drug formulation by X-ray diffraction and 
hence suggested that the crystallization reduced the drug 
diffusion direction and improved a highly ordered 
orientation. 
Cheng YY et al. 35 investigated transdermal delivery of 
nonsteroidal anti-inflammatory drugs mediated by 
PAMAM dendrimers. Ketoprofen and Diflunisal were used 
as model drugs. In vitro permeation studies on excised rat 
skins indicated that PAMAM dendrimers significantly 
enhanced the steady-state flux of both drugs, compared to 
the drug suspensions without PAMAM dendrimers. A 
possible explanation for this transdermal-enhancing effect 
is that dendrimers increased the water solubility of NSAIDs 
therefore solubilities of both ketoprofen and diflunisal was 
dramatically increased in the presence of PAMAM 
dendrimers. Alternatively, the large number of primary 
amines with cationic charges on the surface of dendrimers 
could conceivably alter the skin barrier function and 
enable NSAIDs-PAMAM dendrimer complexes to pass 
through.  
Dendrimers in Ocular Drug Delivery: The main challenge 
in ocular drug delivery is to increase the drug 
bioavailability and prolong the residence time of the drug 
on the cornea, conjunctiva, and corneal epithelia. Up to 
now, different polymeric formulations, such as natural 
polymers, bioadhesive polymers, and colloidal 
formulations, have been used as potential ophthalmic drug 
carriers 36. These polymeric formulations with perfect 
viscosity can prolong the drugs’ residence time on the 
cornea and increase their bioavailability. However, most of 
these formulations give rise to unwanted side effects 37.  
Polymeric nanoparticles tend to be removed by lachrymal 
drainage whereas microparticulates of larger sizes are less 
tolerable because they may cause eye irritation and tend to 
be eliminated by the flow of tears.  Additionally, 
administration of these polymers to the cornea may lead to 
blurred vision resulting from infiltration of the lachrymal 
gland with round cells and reduced secretion of lachrymal 
fluid. Overall, development of new functional materials to 
avoid these problems still holds the key for the future 
ocular drug delivery. Recently, dendrimers with distinct 
properties from traditional polymers were suggested to act 
as ophthalmic vehicles in ocular delivery systems. These 
dendritic polymers might dissolve hydrophobic drugs in 
their cavities and accomplish both retention and 
sustained/controlled release of drugs. Vandamme and 
Brobeck 38 have reported the development of using 
PAMAM dendrimers as ophthalmic vehicles in ocular 
delivery systems. Pilocarpine nitrate and Tropicamide 
were employed as model drugs for miotic and mydriatic 
activity tests, respectively. Under the same experimental 
conditions, the mean ocular residence times of PAMAM 
dendrimer aqueous solutions (G1.5, G2- OH, G4-OH)) were 
found to be comparable to that of the 0.2% w/v Carbopo1 
solution, which is a well-known bioadhesive polymer for 
ophthalmic dosage forms. The ocular residence time of the 
G2 dendrimer solution was even significantly longer than 
that of Carbopol or HPMC solutions. The results obtained 
from the miotic and mydriatic activity tests on rabbits 
indicated that the pharmacological activities of pilocarpine 
nitrate and tropicamide were much greater when they 
were co-administrated with PAMAM dendrimers. The eye 
drops containing PAMAM dendrimers were also found to 
have a prolongation of miotic/mydriatic activity. All the 
three PAMAM dendrimer solutions (Gn–NH2, Gn–OH, and 
Gn–COOH) significantly improved the bioavailability of 
pilocarpine nitrate and tropicamide when compared with 
phosphate solutions containing these drugs. The authors 
explained that the increased bioavailability of pilocarpine 
nitrate was neither contributed to the difference of pH 
conditions in the reference solutions nor associated with 
the interactions between the dendrimers and drug 
molecules. However, it might be contributed to (1) the 
host–guest relationship between dendrimers and drug 
molecules, which induced slower release of these drugs 
encapsulated in dendrimers’ interior cavities and (2) the 
bioadhesive properties of PAMAM dendrimers, which can 
be explained by the structure, shape, and surface 
functional groups of dendrimers. The influence of 
dendrimer concentration and surface functional groups for 
controlled ocular drug delivery was also determined, and 
the results suggested that dendrimer size, molecular 
weight, charge intensity, and molecular geometry 
influenced ocular delivery efficiency.  
Shaunak et al. [39] used carboxylated PAMAM dendrimer 
(G3.5) to synthesize dendrimer-glucosamine (DG) and 
dendrimer-glucosamine 6-sulfate (DGS) conjugates with 
immuno-modulatory and anti-angiogenic properties, 
respectively. These two conjugates were used together in a 
validated and clinically relevant rabbit model of wound 
healing after glaucoma filtration surgery to increase the 
long-term success of the surgery and prevent scar tissue 
formation. DG (60.30 mg/ animal) and DGS (30.15 
mg/animal) were administered by subconjunctival 
injection. Bleb survival was evaluated as the primary 
efficacy end point of treatment. The results showed that 
combination subconjunctival treatment with DG and DGS 
increased the long-term success of the surgery from 30% 
to 80% and inhibited the pro inflammatory and pro-
angiogenic responses in these animals. Rabbits treated 
with DG and DGS showed minimal scar tissue formation 
compared to placebo-treated animals. Furthermore, no 
clinical, haematological, or biochemical toxicity, or 
microbial infections were found in all animals during the 
whole experimental period. The results suggested that 
ocular administration of DG and DGS might be effective, 
reasonable, and safe routes in clinical practice.  
As estimated by the World Health Organization (WHO), 
corneal diseases are the major causes of blindness. 
Although traditional allograft cornea transplantation has a 
satisfactory success rate, lack of corneal tissue is still the 
major problem which prevents these blind people from the 
light. Therefore, it is desirable to find artificial corneas that 
can be able to replace the damaged ones in patients. 
Recently, Duan and Sheardown 40 used G2 PPI dendrimer 
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to prepare highly cross-linked collagen with mechanical 
properties and applied it as a corneal tissue-engineering 
scaffold. The artificial biomaterial was shown to have much 
better mechanical properties, adhesion ability, optical 
transparency, and glucose permeability than natural 
human cornea as well as EDC and glutaraldehyde cross-
linked collagen. In vitro culture of human corneal epithelial 
cells on dendrimer cross-linked collagen gels was used to 
confirm that the presence of dendrimers did not adversely 
affect the biocompatibility of the gels. The results 
suggested dendrimer-cross-linked collagen supported the 
human corneal epithelial cell growth and adhesion without 
cell toxicity. Overall, these results indicated that 
dendrimers could be successfully applied for collagen 
crosslinking to produce transparent, mechanically 
stronger, and more biocompatible collagen gels. 
Dendrimer cross-linked collagen gels can also be used to 
develop various collagen-based tissue engineering 
scaffolds and may be applied as suitable scaffolds for 
artificial corneal and many other tissue engineering 
applications.  
Dendrimers in Targeted Drug Delivery: Star-burst 
dendrimers represent a superior carrier platform for 
targeted drug delivery. Yang et al. 41 reported targeting 
cancer cells with biotin–dendrimer conjugates. Partially 
acetylated generation 5 (G5) polyamidoamine (PAMAM) 
dendrimer was conjugated with the targeting moiety 
(biotin) and the imaging moiety 
(fluoresceinisothiocyanate, FITC), and the flow cytometry 
and confocal microscopy study  revealed that  resulting 
dendrimer–biotin –FITC conjugate exhibited much higher 
cellular uptake into HeLa cells than the conjugate without 
biotin. The uptake was energy-dependent, dose-dependent, 
and could be effectively blocked by dendrimer-conjugated 
biotin. Therefore biocompatible biotin–dendrimer 
conjugate might be a promising nano-platform for cancer 
therapy and cancer diagnosis. 
Dendrimers can also be used as coating agents to protect 
or deliver drugs to specific sites in the body or as time-
release vehicles for biologically active agents. 5-
Fluorouracil (5FU) is known to have remarkable 
antitumour activity, but it has high toxic side effects. 
PAMAM dendrimers after acetylation can form dendrimer-
5FU conjugates. The dendrimers are water soluble and 
hydrolysis of the conjugates releases free 5FU. The slow 
release reduces 5FU toxicity. Such dendrimers seem to be 
potentially useful carriers for antitumour drugs 42. 
Choi et al. 43 reported Dendrimer-based multivalent 
vancomycin nanoplatform for targeting the drug-resistant 
bacteria surface. Vancomycin represents the preferred 
ligand for bacteria-targeting nanosystems. However, it is 
inefficient for emerging vancomycin-resistant species 
because of its poor affinity to the reprogrammed cell wall 
structure. Therefore resarchers reported the use of a 
multivalent strategy as an effective way for overcoming 
such an affinity limitation in bacteria targeting.  They 
designed a series of fifth generation (G5) 
poly(amidoamine) (PAMAM) dendrimers tethered with 
vancomycin at the C-terminus at different valencies and  
performed surface plasmon resonance (SPR) studies to 
determine their binding avidity to two cell wall models, 
each made with either a vancomycin-susceptible (D)-Ala-
(D)-Ala or vancomycin-resistant (D)-Ala-(D)-Lac cell wall 
precursor. These conjugates showed remarkable 
enhancement in avidity in the cell wall models tested, 
including the vancomycin-resistant model, which had an 
increase in avidity of four to five orders of magnitude 
greater than free vancomycin. The tight adsorption of the 
conjugate to the model surface corresponded with its 
ability to bind vancomycin-susceptible Staphylococcus 
aureus bacterial cells in vitro were imaged by confocal 
fluorescent microscopy. This vancomycin platform was 
then used to fabricate the surface of iron oxide 
nanoparticles by coating them with the dendrimer 
conjugates, and the resulting dendrimer-covered magnetic 
nanoparticles were demonstrated to rapidly sequester 
bacterial cells. Thus the researchers successfully 
investigates the biophysical basis of the tight, multivalent 
association of dendrimer-based vancomycin conjugates to 
the bacterial cell wall, and proposed a potential new use of 
this nanoplatform in targeting Gram-positive bacteria. 
Dendrimers for Controllable Gene Therapy/Non-Viral 
Gene Delivery: Dendrimers can act as carriers, called 
vectors, in gene therapy. Vectors transfer genes through 
the cell membrane into the nucleus. Currently liposomes 
and genetically engineered viruses have been mainly used 
for this. PAMAM dendrimers have also been tested as 
genetic material carriers 44. They are terminated in amino 
groups which interact with phosphate groups of nucleic 
acids. This ensures consistent formation of transfection 
complexes. A transfection reagent called SuperFect TM 
consisting of activated dendrimers is commercially 
available. Activated dendrimers can carry a larger amount 
of genetic material than viruses. SuperFect–DNA 
complexes are characterised by high stability and provide 
more efficient transport of DNA into the nucleus than 
liposomes. The high transfection efficiency of dendrimers 
may not only be due to their well-defined shape but may 
also be caused by the low pK of the amines (3.9 and 6.9). 
The low pK permit the dendrimer to buffer the pH change 
in the endosomal compartment 45.  PAMAM dendrimers 
functionalized with cyclodextrin showed luciferase gene 
expression about 100 times higher than unfunctionalized 
PAMAM or non-covalent mixtures of PAMAM and 
cyclodextrin. Dendrimers of high structural flexibility and 
partially degraded high-generation dendrimers (i.e., hyper 
branched architectures) appear to be better suited for 
certain gene delivery operations than intact high-
generation symmetrical dendrimers 46. 
Dendrimers as Bio Mimetic Artificial Proteins and 
Vaccines  
Dendrimers are often referred to as “artificial proteins” 
due to their dimensional length scaling, narrow size 
distribution, and other bio mimetic properties 47.  For 
examples PAMAM family, they closely match the sizes and 
contours of many important proteins and bio assemblies 
like insulin (3 nm), cytochrome C (4 nm), and haemoglobin 
(5.5 nm) are approximately the same size and shape as 
ammonia-core PAMAM dendrimers generations 3, 4 and 5, 
respectively. Generation 2 dendrimer matches the width 
(2.4 nm) of DNA duplexes (form stable complexes with 
histone clusters to condense and store DNA within the 
nucleosome of cells.) and generations 5 and 6 PAMAM 
dendrimers have diameters approximately equivalent to 
the thickness of lipid bilayer membranes (~5.5 nm) of 
biological cells. Unlike the classic polymers, dendrimers 
are rather monodispersed (polydispersity close to 1.00), 
which makes them very similar to biomacromolecules such 
as proteins. They can be synthetically designed to mimic 
various biological functions of metalloproteins and 
enzymes such as supramolecular self-assembly, molecular 
recognition and complexation, etc. 48. Researchers have 
designed an amphiphilic peptide dendrimer as a synthetic 
AIDS Vaccine, capable of forming liposomes or micelles by 
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attaching tripalmitoy1s-glycery1 cysteine group to a 
tetravalent peptide antigen containing glycoprotein gp 120 
of HIV-1 virus. Starburst dendrimers used for enhanced 
performance and flexibility for immunoassays. On the basis 
of feasibility studies with model systems it was concluded 
that immunoassays can be developed with performance 
equivalent to or better than that in many established 
systems and demonstrated enhanced sensitivity for 
creatinnie kinase MB isoenzyme (CKBB), thyrotropin and 
myoglobin assays and reduced instrumental analysis time 




Boron Neutron Capture Therapy (BNCT) 
In this method, the patient is first injected with a 
pharmaceutical which moves to cancer cells. This drug 
contains a stable isotope of boron, to which dendrimers 
have been attached with covalent bonds 49. Then, a neutral 
beam of low energy/thermal electrons is applied to the 
patient, which in turn destroys the tumor but leaves the 
healthy cells behind. Such an innovation is so crucial to 
cancer treatment because current methods such as 
chemotherapy and radiation therapy cause much harm to 
healthy cells instead of just cancerous ones. Boronated 
starburst PAMAM (i.e. polyamidoamine) dendrimer-
monoclonal antibody immunoconjugates have been used 
as potentially efficient anti-cancer reagents involving 
boron capture of neutron (Figure 6). 
 
 
Figure 6: Antibody-Targeted Dendritic Nanodevice for Boron Neutron Capture Therapy 
 
Dendrimer as Solubility Enhancers 
There are many substances which have a strong 
therapeutic activity but, due to their lack of solubility in 
pharmaceutically acceptable solvents, they have not been 
used for therapeutic purposes. Water soluble dendrimers 
are capable of binding and solubilising small acidic 
hydrophobic molecules with antifungal or antibacterial 
properties. Dendrimers having a hydrophobic core and a 
hydrophilic surface layer, have been termed unimolecular 
micelles. Unlike traditional micelles, dendrimers do not 
have a critical micelle concentration. This characteristic 
offers the opportunity to solubilize poorly soluble drugs by 
encapsulating them within the dendritic structure at all 
concentrations of dendrimer. A hydrophilic– hydrophobic 
core-shell dendrimer with PAMAM interior and long alkane 
chain exterior was shown to bind 5-flurouracil, a water-
soluble anti-tumor drug 50. After a phospholipid coating of 
the dendrimer−fatty−acid macromolecule, oral 
bioavailability in rats of 5-flurouracil was nearly twice the 
level of free 5-flurouracil. Dendrimer-based carriers could 
offer the opportunity to enhance the oral bioavailability of 
problematic drugs. Propranolol when conjugated to 
surface of modified G3 PAMAM dendrimer, the solubility of 
propranolol increased by over two orders of magnitude. 
Thus, dendrimer nanocarriers offer the potential to 
enhance the bioavailability of drugs that are poorly soluble 
and/or substrates for efflux transporters.  
Exploring Dendrimer towards Dual Drug Delivery with 
its pH Responsive Simultaneous Drug-Release Kinetics: 
A major problem associated with conventional leukaemia 
chemotherapy is the development of resistance that can be 
surmounted well by combination chemotherapy. Tekade et 
al. 51 reported a novel technology to load two anti-
leukaemic drugs of choice simultaneously inside the 
PAMAM dendrimer. Under optimized conditions of pH and 
dialysis time, one molecule of PAMAM dendrimer was 
found to be capable of entrapping 27.02 ± 0.51 and 8.00 ± 
0.46 molecules of Methotrexate and all-trans Retinoic acid 
(ATRA), respectively. The simultaneous in-vitro release 
profiling of the loaded drugs was studied at pH 4, 7.4 and 
10. The release kinetics was found to be governed by 
degree of dendrimer protonation, with more sustained and 
controlled behaviour at pH 7.4. Terminal loading of 
dendrimer with less haemolytic bioactive (ATRA) reduced 
the haemolytic toxicity of the dendrimer formulation. A 
cytotoxicity study was also performed on HeLa cell lines 
by MTT assay, wherein after 72 h, the dual-drug loaded 
dendrimer was found to be more efficient (IC50 0.5 µM) as 
compared to that of the free drug combination (IC50 0.75 
µM). 
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Dendrimer-Based Postnatal Therapy for 
Neuroinflammation and Cerebral Palsy in a Rabbit 
Model: Cerebral palsy (CP) is a chronic childhood disorder 
with no effective cure. Neuroinflammation, caused by 
activated microglia and astrocytes, plays a key role in the 
pathogenesis of CP and disorders such as Alzheimer’s 
disease and multiple sclerosis. Targeting 
neuroinflammation can be a potent therapeutic strategy. 
However, delivering drugs across the blood-brain barrier 
to the target cells for treating diffuse brain injury is a major 
challenge. Kannan et al. 52 revealed that systemically 
administered polyamidoamine dendrimers localized in 
activated microglia and astrocytes in the brain of newborn 
rabbits with CP, but not healthy controls. Researchers 
demonstrated that dendrimer-based N-acetyl-L-cysteine 
(NAC) therapy for brain injury suppresses 
neuroinflammation and leads to a marked improvement in 
motor function in the CP kids. The well-known and safe 
clinical profile for NAC, when combined with dendrimer-
based targeting, provides opportunities for clinical 
translation in the treatment of neuroinflammatory 
disorders in humans. The effectiveness of the dendrimer-
NAC treatment, administered in the postnatal period for a 
prenatal insult, suggested a window of opportunity for 
treatment of CP in humans after birth. 
Dendrimers in Photodynamic Therapy (PDT)  
Cancer treatment involves the administration of a light 
activated photosensitizing drug that selectively 
concentrates in diseased tissue. For example the 
photosensitizer 5-aminolevulinic acid has been attached to 
the surface of dendrimers and studied as an agent for PDT 
of tumorigenic keratinocytes 53.  
 Diagnostic Applications:  Dendrimers are the few 
types of synthetic polymers that can be precisely 
controlled in size and structure. The well-defined structure 
renders dendritic macromolecules unique properties for 
versatile applications, especially in the biomedical field 54. 
Dendrimers as Molecular Probes: Due to their distinct 
morphology and unique characteristics,  dendrimers  are 
used as molecular probes. For Example, the immobilization 
of sensor units on the surface of dendrimers is a very 
efficient way to generate an integrated molecular probe, 
because of their large surface area and high density of 
surface functionalities 55. 
Dendrimers as X-ray contrast agents: Dendrimers are 
currently under investigation as potential polymeric X-ray 
contrast agents. Potential dendritic X-ray contrast agents 
using various organo metallic complexes such as bismuth 
and tin are used to obtain a high resolution X-ray image, 
several diseases or organs, such as arteriosclerotic 
vasculature, tumors, infarcts, kidneys or efferent urinary 
etc. 
Dendrimers as Magnetic Resonance Imaging (MRI) 
contrast agents: Dendrimer based metal chelates act a 
magnetic resonance imaging contrast agent. Target specific 
moieties are attached to the dendritic MRI contrast agents, 
to improve the pharmacokinetic properties of dendrimer 
contrast agents, for example folate conjugated Gd (III)–
DTPA PAMAM dendrimer, which increased the longitudinal 
relaxation rate of tumor cells expressing the high affinity 
folate receptor. Dendrimers have the ability to deliver drug 
inside the cell or they may improve intracellular 
trafficking. The sixth generation polygadolinium  
dendrimer displayed a prolonged enhancement time and is 
extremely useful for 3D time-of-flight MR angiography. 
Commercially available dendrimers such as PAMAM and 
PPI (polypropyleneimine) dendrimer have also been 
employed as magnetic resonance imaging contrast agents 
potentially to improve the quality of the clinical diagnostics 
56. 
Cardiac Testing: Dade International Inc. (U.S.A.) has 
introduced a new method in cardiac testing. Proteins 
present in a blood sample bind to immunoglobulins which 
are fixed by dendrimers to a sheet of glass. The result 
shows if there is any heart muscle damage. This method 
significantly reduces the waiting time for the blood test 
results (to about 8 min). When a randomly organised 
solution of immunoglobulins is used the test lasts up to 40 
min. Conjugates of dendrimer and antibody improve also 
precision and sensitivity of the test. 
Biochemical analysis: The design of sugar binding 
receptor for detection of sugar level in diabetic patients by 
introducing boronic acid base fluorescence sensor. The 
anthracene units (chromophore) and boronic acid (sugar 
bindinig moiety) were attached to second generation 
PAMAM dendrimer through a tertiary amine. Used for 
Steric isolation of the methalloporphyrin, this is important 
to achieve certain biological function 57.  
 Dendritic Catalysts / Enzymes  
Dendrimers are useful as nanoscale catalysts due to its 
combination of high surface area and high solubility.  
Dendrimers combine the advantages of homogenous and 
heterogeneous catalysts. Homogenous catalysts are 
effective due to a good accessibility of active sites but they 
are often difficult to separate from the reaction stream. 
Heterogeneous catalysts are easy to separate from the 
reaction mixture but the kinetics of the reaction is limited 
by mass transport. Dendrimers have a multifunctional 
surface and all catalytic sites are always exposed towards 
the reaction mixture. They can be recovered from the 
reaction mixture by easy ultrafiltration methods. Dendritic 
shells can be used to create a microenvironment which is 
favourable for catalysis or provide shielding for functional 
groups at the dendritic core .The first example of a catalytic 
dendrimer was described by the group of Koten et al. 58. 
They terminated soluble polycarbosilane dendrimers in 
diamino arylnickel (II) complexes. Such dendrimers can be 
used in addition reactions of polyhaloalkanes. 
 Industrial Processes  
Dendrimers can encapsulate insoluble materials, such as 
metals, and transport them into a solvent within their 
interior. For example, fluorinated dendrimers, which are 
soluble in supercritical CO2 and can be used to extract 
strongly hydrophilic compounds from, water into liquid 
CO2. This may help develop technologies in which 
hazardous organic solvents are replaced by liquid CO2.  
8. FUTURE SCOPE OF DENDRIMERS  
The dendrimers holds a promising future in various 
pharmaceutical applications and diagnostic field in the 
coming years as they possess unique properties, such as 
high degree of branching, multivalency, globular 
architecture and well-defined molecular weight, there by 
offering scaffold for drug delivery. Specified drug delivery, 
especially regarding cancer is the primary future 
application, but there are countless others, including: 
vectors in gene therapy, solubility enhancers, 
photodynamic therapy, and industrial processes. Because 
of their unique cascade architecture, dendrimers can 
coordinate with metal ions selectively on different 
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structural locations such as the surface, core, or branching 
focal point. These distinct features have attracted great 
attention among scientists in many disciplines including 
organic, inorganic, organometallic, polymer, physical and 
biochemistry as well as materials science. Unique 
magnetic, electronic and optical properties have been 
intensively explored in dendritic materials. Dendrimer 
research has indeed become an interdisciplinary topic with 
a great influence on wide fields of science and technology. 
The research endeavours such as a novel organoplatinum 
antitumor prodrug based on the fourth generation PAMAM 
dendrimer for potential control-release of active platinum 
species in cancer treatment by Howell B et al.59,  Klajnert B 
et al. 60 investigation on haemotoxicity of PAMAM 
dendrimers and Chauhan A et al. 61  report on pre-clinical 
and behavioural toxicity profile of PAMAM dendrimers in 
mice  demonstrate control of molecular properties for a 
variety of biomedical applications in the design of unique 
dendrimer structures. Such a task needs the collaborative 
efforts of synthetic chemists, material engineers and 
molecular biologists as well as industry experts. Several 
dendrimer based products have been approved by the FDA 
and some are in Phase II clinical trials. Various dendrimer 
based products are: 
(1) Alert ticket for Anthrax Detection 
(2) Priofect™, Priostar™ and Starburst for targeted 
diagnostic, therapeutic delivery for cancer cells 
(3) SuperFect for Gene Transfection 
(4) Stratus CS for Cardiac Marker 
(5) Vivagel for preventing HIV 
9. CONCLUSION 
The possibility of medicinal and practical advances that 
dendrimers could lead to is endless. That possibility makes 
dendrimers a truly interesting topic of research. Recent 
success in simplifying and optimizing the synthesis of 
dendrimers provide a large variety of structures with 
reduced cost of their production. Although, as has been 
apparent by the many instances cited throughout this 
review where gaps in knowledge still remain and that must 
be plugged before dendrimers are ready for wide clinical 
use, their extreme versatility combined with the extensive 
research efforts now underway are sure to add 
sophistication to drugs already in use as well as spur the 
development of entirely new classes of therapeutics. 
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